<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href="http://www.blogger.com/styles/atom.css" type="text/css"?><feed xmlns='http://www.w3.org/2005/Atom' xmlns:openSearch='http://a9.com/-/spec/opensearchrss/1.0/' xmlns:blogger='http://schemas.google.com/blogger/2008' xmlns:georss='http://www.georss.org/georss' xmlns:gd="http://schemas.google.com/g/2005" xmlns:thr='http://purl.org/syndication/thread/1.0'><id>tag:blogger.com,1999:blog-3419574715343165986</id><updated>2024-11-05T21:02:35.424-06:00</updated><category term="Industria Farmaceutica"/><category term="Novartis"/><category term="Noticias breves"/><category term="GSK"/><category term="Merck y Co."/><category term="Material Promocional"/><category term="Puestos y Nombres"/><category term="Efectos Adversos"/><category term="Multas y Demandas"/><category term="Nuevos productos"/><category term="Pfizer"/><category term="AstraZeneca"/><category term="BMS"/><category term="Marketing"/><category term="Estudios Clínicos"/><category term="Lilly"/><category term="Patentes"/><category term="Recursos Humanos"/><category term="Registros y Aprobaciones"/><category term="Compliance"/><category term="Fuerzas de Ventas"/><category term="Prexige"/><category term="Recortes"/><category term="Estudios"/><category term="FDA"/><category term="Fusiones"/><category term="SP"/><category term="Vioxx"/><category term="Wyeth"/><category term="Abbott"/><category term="Bayer"/><category term="Capacitación"/><category term="Encuestas Ind Pharm"/><category term="RD"/><category term="Regulaciones"/><category term="Sanofi-Aventis"/><category term="Alianzas"/><category term="EMC"/><category term="Eventos Científicos"/><category term="Liderazgo"/><category term="Muestra Medica"/><category term="Roche"/><category term="Valeant"/><category term="Video Ind Pharma"/><category term="Bienvenida"/><category term="Campañas"/><category term="Diabamet"/><category term="Diaberil"/><category term="Incentivos"/><category term="Internet"/><category term="JnJ"/><category term="Lanzamientos"/><category term="Pharmmicks"/><category term="Rasilez"/><category term="YouTube"/><category term="eutica"/><title type='text'>Pharmmicks</title><subtitle type='html'>El Blog en español para la Industria Farmacéutica</subtitle><link rel='http://schemas.google.com/g/2005#feed' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/posts/default'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default?redirect=false'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/'/><link rel='hub' href='http://pubsubhubbub.appspot.com/'/><link rel='next' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default?start-index=26&amp;max-results=25&amp;redirect=false'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><generator version='7.00' uri='http://www.blogger.com'>Blogger</generator><openSearch:totalResults>210</openSearch:totalResults><openSearch:startIndex>1</openSearch:startIndex><openSearch:itemsPerPage>25</openSearch:itemsPerPage><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-7656663121779339288</id><published>2008-09-11T22:17:00.001-05:00</published><updated>2008-09-11T22:17:50.894-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="GSK"/><category scheme="http://www.blogger.com/atom/ns#" term="Puestos y Nombres"/><title type='text'>Nuevo CEO en Sanofi-Aventis</title><summary type="text"> El día de ayer Sanofi-Aventis anunció que Chris Viehbacher reemplazará al CEO Gerard Le Fur a partir del primero de diciembre de este año.  La empresa comentó que se necesitaba el cambio para implementar nuevas estrategias mientras que versiones no oficiales mencionaron que Le Fur perdió el apoyo del consejo de administración</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/7656663121779339288/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/7656663121779339288?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7656663121779339288'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7656663121779339288'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/nuevo-ceo-en-sanofi-aventis.html' title='Nuevo CEO en Sanofi-Aventis'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5330825249894603337</id><published>2008-09-07T22:38:00.000-05:00</published><updated>2008-09-07T22:39:30.161-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Compliance"/><category scheme="http://www.blogger.com/atom/ns#" term="Novartis"/><title type='text'>Novartis patrocina evento en la Convención Nacional Republicana</title><summary type="text">The News &amp;amp; Observer publicó el viernes que la compañía farmacéutica patrocinó un evento para la delegación de Carolina del Norte. Según el artículo la empresa llevó a los delegados en autobús al lago Minnentonka en las afueras de Minneapolis para tomar parte en una cena dentro de un country club. Incluso se menciona que hubo tours en botes.Dentro del menú había momosas, blody marys, vino y un</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5330825249894603337/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5330825249894603337?isPopup=true' title='1 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5330825249894603337'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5330825249894603337'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/novartis-patrocina-evento-en-la.html' title='Novartis patrocina evento en la Convención Nacional Republicana'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>1</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-3608251134333473433</id><published>2008-09-04T23:08:00.001-05:00</published><updated>2008-09-04T23:08:50.282-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Alianzas"/><category scheme="http://www.blogger.com/atom/ns#" term="Pfizer"/><title type='text'>Pfizer compra producto para Alzheimer por $725 millones de USD</title><summary type="text">En un intento por llenar la “pipeline”  y conseguir urgentemente un nuevo “blockbuster” Pfizer negoció con Medivation la comercialización de  Dimebon (diembolin). La negociación incluye un pago anticipado de $225 millones y los otros $500 dependen de el logro de diferentes objetivos</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/3608251134333473433/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/3608251134333473433?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/3608251134333473433'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/3608251134333473433'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/pfizer-compra-producto-para-alzheimer.html' title='Pfizer compra producto para Alzheimer por $725 millones de USD'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-7276939388380377994</id><published>2008-09-04T23:06:00.000-05:00</published><updated>2008-09-04T23:08:00.759-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="BMS"/><category scheme="http://www.blogger.com/atom/ns#" term="Recortes"/><title type='text'>BMS vende su flota aérea</title><summary type="text">En un anuncio publicado el día de ayer, se informa que BMS venderá su flota de 4 aparatos y despedirá a 32 empleados entre pilotos, técnico y demás personal.La flota consiste de 2 jets Gulfstream V y dos helicópteros Sikorsky S-76C. El costo de los jets es de aprox. $40 millones cada uno y el de los helicópteros alrededor de $6 millones cada unoEstas acciones son parte de un plan para reducir </summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/7276939388380377994/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/7276939388380377994?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7276939388380377994'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7276939388380377994'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/bms-vende-su-flota-area.html' title='BMS vende su flota aérea'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-1196316327107267189</id><published>2008-09-04T23:04:00.001-05:00</published><updated>2008-09-04T23:06:11.085-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Pharmmicks"/><title type='text'>Pharmmicks en 150 ciudades de México</title><summary type="text">Pharmmicks es consultado ya por lectores en 150 ciudades de la República Mexicana.Un saludo a los colegas de Pfizer que con los lectores que mas entran al blog.Sería muy interesante el tener mayor participación de los lectores con el fin de enriquecer la página y poder discutir temas que impactan a la industria farmacéutica. Para cualquier duda o comentario enviar correos a: pharmmicks@gmail.com</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/1196316327107267189/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/1196316327107267189?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1196316327107267189'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1196316327107267189'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/pharmmicks-en-150-ciudades-de-mxico.html' title='Pharmmicks en 150 ciudades de México'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5333076225175314076</id><published>2008-09-02T23:03:00.002-05:00</published><updated>2008-09-02T23:05:10.564-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Liderazgo"/><title type='text'>Steve Jobs en Stanford</title><summary type="text"> Liderazgo y motivaciónRecientemente encontré un video que  Steve Jobs dió a estudiantes de Stanford. Generalmente  logró ver los primeros 15 segundos de los video en internet, sin embargo, les recomiendo mucho que vean las dos partes.   EXCELENTE !!!Como me gustaría poder presenciar discursos de este tipo en nuestras compañías, o que los líderes de estas empresas puedan enseñarnos o compartir su</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5333076225175314076/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5333076225175314076?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5333076225175314076'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5333076225175314076'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/steve-jobs-en-stanford.html' title='Steve Jobs en Stanford'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5002359560264897663</id><published>2008-09-02T23:03:00.001-05:00</published><updated>2008-09-02T23:03:08.426-05:00</updated><title type='text'>Steve Jobs 1º Parte Discurso con Subtítulos en Español</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5002359560264897663/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5002359560264897663?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5002359560264897663'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5002359560264897663'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/steve-jobs-1-parte-discurso-con.html' title='Steve Jobs 1º Parte Discurso con Subtítulos en Español'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-6264176997944470892</id><published>2008-09-02T23:02:00.001-05:00</published><updated>2008-09-02T23:02:52.994-05:00</updated><title type='text'>Steve Jobs 2º Parte Discurso con Subtítulos en Español</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/6264176997944470892/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/6264176997944470892?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/6264176997944470892'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/6264176997944470892'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/09/steve-jobs-2-parte-discurso-con.html' title='Steve Jobs 2º Parte Discurso con Subtítulos en Español'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5411135892597255512</id><published>2008-08-31T22:20:00.000-05:00</published><updated>2008-08-31T22:21:09.132-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Alianzas"/><category scheme="http://www.blogger.com/atom/ns#" term="GSK"/><category scheme="http://www.blogger.com/atom/ns#" term="Valeant"/><title type='text'>Alianza de $820 millones entre GSK y Valeant con producto para epilepsia</title><summary type="text">En la alianza GSK podrá comercializar retigabina que aparentemente tiene un futuro prometedor. Aunque retigabina no ha sido sometido para aprobación, los estudios fase III ha tenido buenos resultados.Valeant recibirá $125 millones en un pago inicial y en base a ciertas condiciones podría recibir $545 millones adicionales.</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5411135892597255512/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5411135892597255512?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5411135892597255512'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5411135892597255512'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/alianza-de-820-millones-entre-gsk-y.html' title='Alianza de $820 millones entre GSK y Valeant con producto para epilepsia'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-2516387791884620775</id><published>2008-08-31T22:19:00.000-05:00</published><updated>2008-08-31T22:20:30.624-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Novartis"/><category scheme="http://www.blogger.com/atom/ns#" term="RD"/><title type='text'>Corta Novartis inversión en antibiótico. Absorbe pérdida de $235 millones</title><summary type="text">El antibiótico Aurgrab no continuará en el portafolio de Novartis debido a la poca eficacia en los estudios de fase II. El costo de los $235, millones impactarán en el tercer cuarto</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/2516387791884620775/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/2516387791884620775?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2516387791884620775'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2516387791884620775'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/corta-novartis-inversin-en-antibitico.html' title='Corta Novartis inversión en antibiótico. Absorbe pérdida de $235 millones'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-2796593348832871999</id><published>2008-08-31T22:18:00.000-05:00</published><updated>2008-08-31T22:19:39.499-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Recortes"/><title type='text'>UCB recorta 2000 posiciones</title><summary type="text">Como parte de un plan para darle un nuevo enfoque a la compañía, UCB cortará 2000 posiciones equivalentes al 17% de su fuerza laboral. El objetivo en convertirse en una compañía especializada en sistema nerviosos central e inmunología.Una cuarta parte de los empleos recortados serán en las plantas de Bélgica</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/2796593348832871999/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/2796593348832871999?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2796593348832871999'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2796593348832871999'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/ucb-recorta-2000-posiciones.html' title='UCB recorta 2000 posiciones'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-2389863972037612871</id><published>2008-08-16T17:39:00.003-05:00</published><updated>2008-08-16T17:39:49.215-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Abbott"/><category scheme="http://www.blogger.com/atom/ns#" term="AstraZeneca"/><title type='text'>Alianza entre Abbott y AstraZeneca</title><summary type="text"> Recientemente se  anunció una alianza entre las dos compañías para que Abbott promovieran Crestor en los EUA. Con esta acción AZ tiene la posibilidad de extender el impacto promocional de Crestor y dominar este atractivo mercado.Interesante es que con la caída de Vytorin, Zetia y el próximo vencimiento de la patente de Lipitor, Crestor le apuesta con todo para alcanzar el liderato absoluto en </summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/2389863972037612871/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/2389863972037612871?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2389863972037612871'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2389863972037612871'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/alianza-entre-abbott-y-astrazeneca_16.html' title='Alianza entre Abbott y AstraZeneca'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-1045922537448904168</id><published>2008-08-16T17:39:00.001-05:00</published><updated>2008-08-16T17:39:48.625-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Abbott"/><category scheme="http://www.blogger.com/atom/ns#" term="AstraZeneca"/><title type='text'>Alianza entre Abbott y AstraZeneca</title><summary type="text"> Recientemente se  anunció una alianza entre las dos compañías para que Abbott promovieran Crestor en los EUA. Con esta acción AZ tiene la posibilidad de extender el impacto promocional de Crestor y dominar este atractivo mercado.Interesante es que con la caída de Vytorin, Zetia y el próximo vencimiento de la patente de Lipitor, Crestor le apuesta con todo para alcanzar el liderato absoluto en </summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/1045922537448904168/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/1045922537448904168?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1045922537448904168'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1045922537448904168'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/alianza-entre-abbott-y-astrazeneca.html' title='Alianza entre Abbott y AstraZeneca'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-6033759014737437231</id><published>2008-08-16T16:35:00.005-05:00</published><updated>2008-08-16T16:49:56.157-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="eutica"/><category scheme="http://www.blogger.com/atom/ns#" term="Industria Farmaceutica"/><title type='text'>Reducción de Precios en Retrovirales en México</title><summary type="text">Hace unas semanas se llevó a cabo en el Distrito Federal el Congreso Mundial de VIH, organizado por la Sociedad Internacional del SIDA.Este foro se aprovechó para que la Secretaría de Salud anunciara que se había llegado a un acuerdo con las principales compañías farmacéuticas para reducir dramáticamente (aprox. 30%) el precio de los ciertos medicamentos para el tratamiento de VIH. Inicialmente </summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/6033759014737437231/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/6033759014737437231?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/6033759014737437231'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/6033759014737437231'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/reduccin-de-precios-en-retrovirales-en.html' title='Reducción de Precios en Retrovirales en México'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-7556543442588106039</id><published>2008-08-16T16:32:00.002-05:00</published><updated>2008-08-16T16:34:52.587-05:00</updated><title type='text'>Regreso a la Actividad</title><summary type="text">Despúes de un periodo alejado del blog, regreso para seguir informando sobre los acontecimientos más importantes de la industra farmacéutica.He recibido varias sugerencias, las cuales pondré en práctica, sin embargo si existen temas reelvantes que se quieran discutir, favor de enviar correo a mi dirección.Saludos</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/7556543442588106039/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/7556543442588106039?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7556543442588106039'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7556543442588106039'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/08/regreso-la-actividad.html' title='Regreso a la Actividad'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5133183281376122272</id><published>2008-05-18T20:17:00.001-05:00</published><updated>2008-05-18T20:17:20.971-05:00</updated><title type='text'>The Rep 18/20 Three Up Minus One</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5133183281376122272/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5133183281376122272?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5133183281376122272'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5133183281376122272'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/rep-1820-three-up-minus-one.html' title='The Rep 18/20 Three Up Minus One'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-7827865593695395354</id><published>2008-05-14T22:42:00.001-05:00</published><updated>2008-05-14T22:44:34.464-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Lilly"/><category scheme="http://www.blogger.com/atom/ns#" term="Regulaciones"/><title type='text'>Lilly, la primera en dar el ejemplo</title><summary type="text">Hace unos días Lilly apoyó una nueva ley del Senado de los EUA en la cual obliga a las empresas farmacéuticas a publicar los pagos realizados a los médicos.La ley se llama “The Physicians Payments Sunshine Act” y el objetivo es que se declaren los regalos y pagos mayores de $500 USD.Esta ley busca implementar un estandar de reportes de los ingresos de los  médicos generados por actividades con la</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/7827865593695395354/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/7827865593695395354?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7827865593695395354'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/7827865593695395354'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/lilly-la-primera-en-dar-el-ejemplo.html' title='Lilly, la primera en dar el ejemplo'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-1983145569820121627</id><published>2008-05-13T22:29:00.001-05:00</published><updated>2008-05-13T22:30:37.016-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Merck y Co."/><title type='text'>Alianza Ranbaxy Merck y Co.</title><summary type="text">A pesar de que hace unos años la empresa americana Merck definiera en sus estrategias que no iba a relacionarse con genéricos, hace unos días se anunció una alianza entre Merck y Co. y Ranbaxy, compañía farmacéutica de genéricos de la India. Se comenta que el acuerdo generará $100 millones de USD para Ranbaxy. En cuanto a los detalles se dio poca información y el acuerdo incluye varios productos </summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/1983145569820121627/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/1983145569820121627?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1983145569820121627'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1983145569820121627'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/alianza-ranbaxy-merck-y-co.html' title='Alianza Ranbaxy Merck y Co.'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-8656803247853614609</id><published>2008-05-11T20:37:00.001-05:00</published><updated>2008-05-11T20:37:36.746-05:00</updated><title type='text'>The Rep 17/20 VFM</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/8656803247853614609/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/8656803247853614609?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/8656803247853614609'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/8656803247853614609'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/rep-1720-vfm.html' title='The Rep 17/20 VFM'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5171801546497621817</id><published>2008-05-07T00:00:00.001-05:00</published><updated>2008-05-10T17:48:57.653-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="BMS"/><title type='text'>BMS vende Convatec en $4,100 millones de USD</title><summary type="text">Como parte del plan de reestructura de BMS, Convatec, el negocio de manejo de heridas se vendió a dos empresas, Nordic Capital Fun y Avista Capital Partners en $4,100 millones de USDEstos movimientos tienen como objetivo el enfocarse en productos biofarmacétuticos de última generación, según James Cornelius</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5171801546497621817/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5171801546497621817?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5171801546497621817'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5171801546497621817'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/bms-vende-convatec-en-4100-millones-de.html' title='BMS vende Convatec en $4,100 millones de USD'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-1138196487521109148</id><published>2008-05-06T23:59:00.000-05:00</published><updated>2008-05-07T00:00:27.496-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Merck y Co."/><category scheme="http://www.blogger.com/atom/ns#" term="Recortes"/><title type='text'>Recortes en Merck y Co.</title><summary type="text">Una semana despúes de que se rechazó el registro de un nuevo tratamiento combinado, Merck and Co. anunció recortes de 1,200 representanes de ventas. Se menciona también que el declive de ventas de  Vytorin sea una razón. Estas acciones se parte de un programa llamado “Plan to Win” que inició en el 2005(Fuente: Pharmatimes.com)</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/1138196487521109148/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/1138196487521109148?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1138196487521109148'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/1138196487521109148'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/recortes-en-merck-y-co.html' title='Recortes en Merck y Co.'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-5844510894402579859</id><published>2008-05-05T21:02:00.000-05:00</published><updated>2008-05-05T21:03:30.374-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Recortes"/><category scheme="http://www.blogger.com/atom/ns#" term="Wyeth"/><title type='text'>Más recortes de Wyeth...</title><summary type="text">Hace una semana la compañía farmacéutica anunció otro recorte de 1,240 posiciones en ventas en un proyecto llamada “Proyecto Impacto”.El recorte es consecuencia de varios problemas que aprobación de nuevos productos. Por otro lado la empresa espera el lanzamiento de un genérico de Protonix, el cual es uno de los productos claves con ventas de $1,900 millones de USD.</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/5844510894402579859/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/5844510894402579859?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5844510894402579859'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/5844510894402579859'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/ms-recortes-de-wyeth.html' title='Más recortes de Wyeth...'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-2659955320727772789</id><published>2008-05-05T20:50:00.001-05:00</published><updated>2008-05-05T20:51:46.793-05:00</updated><category scheme="http://www.blogger.com/atom/ns#" term="Recortes"/><category scheme="http://www.blogger.com/atom/ns#" term="Valeant"/><title type='text'>Recorta Valeant el 50% de su fuerza laboral</title><summary type="text">Recorte en ValeantEl viernes pasado Valeant anunció que reducirá casi en 50% el número de empleados. En cuanto a EUA y México se cortarán de manera inmediata 130 empleos y a nivel mundial se reducirán 1250 posiciones adicionales.Dentro del plan de reestructura se incluye la venta de varias subsidiarias europeas.</summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/2659955320727772789/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/2659955320727772789?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2659955320727772789'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/2659955320727772789'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/recorta-valeant-el-50-de-su-fuerza.html' title='Recorta Valeant el 50% de su fuerza laboral'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-8836278997038577878</id><published>2008-05-05T20:49:00.001-05:00</published><updated>2008-05-05T20:49:17.735-05:00</updated><title type='text'>The Rep 16/20 Innovation</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/8836278997038577878/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/8836278997038577878?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/8836278997038577878'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/8836278997038577878'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/05/rep-1620-innovation.html' title='The Rep 16/20 Innovation'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry><entry><id>tag:blogger.com,1999:blog-3419574715343165986.post-3282230039525008102</id><published>2008-04-14T21:54:00.001-05:00</published><updated>2008-04-14T21:54:41.592-05:00</updated><title type='text'>The Rep 15/20 Face Time</title><summary type="text"></summary><link rel='replies' type='application/atom+xml' href='http://pharmmicks.blogspot.com/feeds/3282230039525008102/comments/default' title='Comentarios de la entrada'/><link rel='replies' type='text/html' href='http://www.blogger.com/comment/fullpage/post/3419574715343165986/3282230039525008102?isPopup=true' title='0 Comentarios'/><link rel='edit' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/3282230039525008102'/><link rel='self' type='application/atom+xml' href='http://www.blogger.com/feeds/3419574715343165986/posts/default/3282230039525008102'/><link rel='alternate' type='text/html' href='http://pharmmicks.blogspot.com/2008/04/rep-1520-face-time.html' title='The Rep 15/20 Face Time'/><author><name>Gimmickmaster</name><uri>http://www.blogger.com/profile/07150892350850192636</uri><email>noreply@blogger.com</email><gd:image rel='http://schemas.google.com/g/2005#thumbnail' width='16' height='16' src='https://img1.blogblog.com/img/b16-rounded.gif'/></author><thr:total>0</thr:total></entry></feed>